Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL
Official Title: A Multicenter Prospective Clinical Study of Venetoclax Combined With Azactidine in the Treatment of Acute Leukaemias of Ambiguous Lineage
Brief Summary: The prognosis of acute leukaemias of ambiguous lineage is poor.
The effect of chemotherapy regimen and hematopoietic stem cell transplantation are still unclear.
Therefore, we will explore new therapy to improve the remission rate of acute leukaemias of ambiguous lineage.
Venetoclax can significantly improve the remission rate and prolong PFS and OS.
At present, venetoclax combined with azacitidine or decitabine has become the preferred treatment regimen for elderly AML patients.
It also shows a high response rate in relapsed/refractory AML or MDS patients.
There are few clinical studies on the treatment of ALAL.
The purpose of this study is to explore the efficacy and safety of venetoclax combined with azacitidine in the treatment of newly diagnosed ALAL patients.